JP2007507519A5 - - Google Patents

Download PDF

Info

Publication number
JP2007507519A5
JP2007507519A5 JP2006534084A JP2006534084A JP2007507519A5 JP 2007507519 A5 JP2007507519 A5 JP 2007507519A5 JP 2006534084 A JP2006534084 A JP 2006534084A JP 2006534084 A JP2006534084 A JP 2006534084A JP 2007507519 A5 JP2007507519 A5 JP 2007507519A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
group
alkoxy
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006534084A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007507519A (ja
JP4879745B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/032104 external-priority patent/WO2005035520A1/en
Publication of JP2007507519A publication Critical patent/JP2007507519A/ja
Publication of JP2007507519A5 publication Critical patent/JP2007507519A5/ja
Application granted granted Critical
Publication of JP4879745B2 publication Critical patent/JP4879745B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006534084A 2003-10-03 2004-09-29 置換イソキノリノン Expired - Fee Related JP4879745B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50840203P 2003-10-03 2003-10-03
US60/508,402 2003-10-03
PCT/US2004/032104 WO2005035520A1 (en) 2003-10-03 2004-09-29 Substituted isoquinolinones

Publications (3)

Publication Number Publication Date
JP2007507519A JP2007507519A (ja) 2007-03-29
JP2007507519A5 true JP2007507519A5 (cg-RX-API-DMAC7.html) 2007-11-08
JP4879745B2 JP4879745B2 (ja) 2012-02-22

Family

ID=34434908

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006534084A Expired - Fee Related JP4879745B2 (ja) 2003-10-03 2004-09-29 置換イソキノリノン

Country Status (10)

Country Link
US (1) US7294635B2 (cg-RX-API-DMAC7.html)
EP (1) EP1667989A4 (cg-RX-API-DMAC7.html)
JP (1) JP4879745B2 (cg-RX-API-DMAC7.html)
KR (1) KR20060113699A (cg-RX-API-DMAC7.html)
CN (1) CN1863789B (cg-RX-API-DMAC7.html)
AU (1) AU2004279809B2 (cg-RX-API-DMAC7.html)
CA (1) CA2539882A1 (cg-RX-API-DMAC7.html)
IL (1) IL174445A (cg-RX-API-DMAC7.html)
MX (1) MXPA06003625A (cg-RX-API-DMAC7.html)
WO (1) WO2005035520A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007003836A (es) * 2004-09-29 2007-08-20 Portola Pharm Inc 2h-1,3-benzoxazin-4(3h)-onas sustituidas.
RU2008101924A (ru) * 2005-07-13 2009-08-20 Астразенека Аб (Se) Новые аналоги пиридина
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
JP2009542641A (ja) * 2006-07-04 2009-12-03 アストラゼネカ アクチボラグ 新規ピリジン類縁体
CA2655629A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab New pyridine analogues
TW200811133A (en) * 2006-07-04 2008-03-01 Astrazeneca Ab New pyridine analogues III 334
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
MX2009007831A (es) 2007-01-22 2010-01-15 Gtx Inc Agentes de union de receptor nuclear.
TW200911755A (en) 2007-04-19 2009-03-16 Astellas Pharma Inc Bicyclic heterocyclic compounds
NZ599556A (en) 2007-05-02 2013-10-25 Portola Pharm Inc Combination therapy with a compound acting as a platelet adp receptor inhibitor
PE20081892A1 (es) * 2007-07-13 2009-02-21 Astrazeneca Ab Nuevos analogos de amino-piridina como agentes antitromboticos
CN103739547B (zh) * 2014-01-03 2015-09-02 沈阳药科大学 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
ES2718175T3 (es) * 2014-12-02 2019-06-28 Lilly Co Eli Compuestos de 1-oxo-1,2-dihidroisoquinolin-7-il-(tiofen-2-il-5-sustituido)-sulfonamida, formulaciones que contienen esos compuestos, y su uso como inhibidores de AICARFT en el tratamiento de cánceres
CN107428696B (zh) 2015-02-16 2021-08-20 昆士兰大学 磺酰脲和相关化合物及其用途
PT3661925T (pt) 2017-07-07 2022-01-31 Inflazome Ltd Novos compostos de sulfonamida-carboxamida
CN111093773A (zh) 2017-08-15 2020-05-01 英夫拉索姆有限公司 作为nlrp3抑制剂的磺酰脲和磺酰硫脲
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
PE20210050A1 (es) 2017-11-09 2021-01-08 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
TWI721624B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
ES2979163T3 (es) 2018-10-31 2024-09-24 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847925A (en) * 1971-07-15 1974-11-12 En Nom Collectif Science Et Ci Benzenesulfonyl semicarbazides
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
EP1047699A1 (en) 1998-01-15 2000-11-02 Cor Therapeutics, Inc. Platelet adp receptor inhibitors
DE60114994T2 (de) * 2000-02-04 2006-08-03 Portola Pharmaceuticals, Inc., South San Francisco Blutplättchen-adp-rezeptor-inhibitoren
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors

Similar Documents

Publication Publication Date Title
JP2007507519A5 (cg-RX-API-DMAC7.html)
JP2008514703A5 (cg-RX-API-DMAC7.html)
JP2007507551A5 (cg-RX-API-DMAC7.html)
CA2540214A1 (en) 2,4-dioxo-3-quinazolinylaryl sulfonylureas
JP2008517983A5 (cg-RX-API-DMAC7.html)
Liverton et al. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase
RU2009110442A (ru) Конденсированные производные имидазола для лечения нарушений, опосредованных альдостеронсинтазой, и/или 11-бета-гидроксилазой, и/или ароматазой
NO20082389L (no) 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler
JP2007508305A5 (cg-RX-API-DMAC7.html)
JP2009543867A5 (cg-RX-API-DMAC7.html)
UY26754A1 (es) Derivados de la 1, 3, 8, -triaza-spiro (4,5) decan-4-ona
WO2002022592A3 (en) Substituted urea neuropeptide y y5 receptor antagonists
JP2008514703A (ja) 置換2h−1,3−ベンゾオキサジン−4(3h)−オン
CA2522435A1 (en) Inhibitors of akt activity
RU2007134380A (ru) Антибактериальные производные пиперидина
CA2668997A1 (en) 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors
MA26870A1 (fr) Derives heterocycliques benzocondenses de nicotinamide utiles comme inhibiteurs selectifs des isozymes pde4
EP1396487A1 (en) Phenylpyridine carbonyl piperazine derivative
RU2009127642A (ru) 1-замещенные производные имидазола и их применение в качестве ингибиторов альдостеронсинтазы
GB0128499D0 (en) Therapeutic agents
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
AR038864A1 (es) Inhibidores pirimidina y piridina biciclicos de la p38 quinasa
CO5630034A2 (es) Procedimiento y composiciones farmaceuticas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
RU2008152247A (ru) Производные циннамоил-пиперазина и их применение в качестве антагонистов par-1
JP2008519087A5 (cg-RX-API-DMAC7.html)